Back

Dong-A ST patent adds to Korea’s race for POLQ cancer drugs

Verifying
  • Dong-A ST published an international patent covering a POLQ-inhibiting compound.
  • $11.2 billion is projected for the 2030 DDR market, versus $5.8 billion in 2024.
  • Daewoong Pharmaceutical is developing DWP223 from 2025 to 2027 for BRCA-mutated solid tumors.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.